Documented nutritional considerations
What approved prescribing information and the scientific literature document about nutrient and co-factor aspects of specific peptide classes — neutral, with sources.
This page only reports what labels and studies document. It is NOT a supplement recommendation, not a stack, and not usage guidance. No dosing, no sourcing. Decisions about supplementation are made together with your doctor.
Bone-building peptides (teriparatide, abaloparatide)
For the approved osteoporosis anabolics, the prescribing information explicitly notes adequate intake of two bone co-factors — not as an extra recommendation from this site, but as part of the approved use.
The label notes adequate calcium intake if the diet is insufficient — calcium is the raw material the bone-building effect relies on.
Source: FDA-Fachinfo Forteo (Teriparatid) ↗The label notes adequate vitamin D intake; vitamin D is required for intestinal calcium absorption.
Source: FDA-Fachinfo Tymlos (Abaloparatid) ↗GLP-1 & incretin agents (semaglutide, tirzepatide, etc.)
With rapid weight loss on incretin agents, the scientific literature discusses accompanying measures to preserve the quality of weight loss. These are not directives from this site but considerations documented in reviews.
In studies a portion of weight loss comes from lean mass; reviews discuss adequate protein intake to help preserve muscle mass.
Source: Review: Nutrition support whilst on GLP-1 therapy (PubMed) ↗The literature discusses resistance training alongside protein intake to limit the share of lean mass lost. (Not a supplement, but a documented accompanying factor.)
Source: Review: Nutrition support whilst on GLP-1 therapy (PubMed) ↗Somatostatin analogues (octreotide, lanreotide, pasireotide)
Somatostatin analogues can inhibit digestive enzyme and bile secretion, which may cause fat malabsorption. The prescribing information documents the resulting nutrient considerations and recommended monitoring.
The label reports depressed vitamin B12 levels in some patients and notes monitoring of B12 levels during therapy.
Source: FDA-Fachinfo Octreotid ↗With the documented fat malabsorption (steatorrhea), fat-soluble vitamins may theoretically be affected; the label advises evaluation if symptoms newly appear or worsen.
Source: FDA-Fachinfo Octreotid ↗Special case: copper peptide (GHK-Cu)
A common misconception: GHK-Cu is itself a copper complex — the co-factor (copper) is part of the molecule. The chemistry does not imply taking an additional copper supplement.
GHK-Cu carries the copper ion as an integral part — this is a chemical property, not an add-on intake.
Source: Wikipedia: Copper peptide GHK-Cu ↗Continuously maintained. Content is for information and education and does not replace medical advice.